Orthocell（OCC）株式概要再生医療企業であるOrthocell Limitedは、オーストラリア、米国、英国、欧州連合において、様々な骨・軟部組織の損傷修復のための細胞療法と生物学的医療機器を開発・商品化している。 詳細OCC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間62.56%増加すると予測されています リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るOCC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.762.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m106m2016201920222025202620282031Revenue AU$105.9mEarnings AU$19.5mAdvancedSet Fair ValueView all narrativesOrthocell Limited 競合他社Aroa BiosurgerySymbol: ASX:ARXMarket cap: AU$223.1mDimerixSymbol: ASX:DXBMarket cap: AU$126.1mActinogen MedicalSymbol: ASX:ACWMarket cap: AU$131.7mRadiopharm TheranosticsSymbol: ASX:RADMarket cap: AU$70.9m価格と性能株価の高値、安値、推移の概要Orthocell過去の株価現在の株価AU$0.7652週高値AU$1.6052週安値AU$0.70ベータ-0.0911ヶ月の変化-6.21%3ヶ月変化2.03%1年変化-36.02%3年間の変化115.71%5年間の変化26.89%IPOからの変化104.05%最新ニュースお知らせ • Apr 17Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital NetworksOrthocell Limited had secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. A significant portion of these facilities could be serviced by the Company's existing distribution footprint, supporting efficient market penetration. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.お知らせ • Apr 14Orthocell Limited to Report Q3, 2026 Results on Apr 20, 2026Orthocell Limited announced that they will report Q3, 2026 results on Apr 20, 2026お知らせ • Nov 20Orthocell Limited Announces Adoption of Remplir by Australian UrologistsOrthocell Limited announced adoption of Remplir™? by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in 100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. This estimate is based on ~ 115,000 prostatectomies performed annually in the U.S., the majority of which are conducted automatically. To capitalise on this opportunity, the Company is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted U.S. product launch in the medium term. Orthocell is also collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets.お知らせ • Nov 14Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,846,154 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 230,770 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 16Orthocell Limited Announces Nerve-Sparing Prostate Cancer SurgeryOrthocell Limited announced its nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market. Summary Points: Australian urologists are using Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications due to peripheral nerve injury -- a development with potential for globally significant impact. Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate. Despite procedures aimed at preserving nerve function (i.e. nerve-sparing), and with the enhanced surgical precision offered by robotic assisted radical prostatectomies (RARP), there remains a significant risk of post-surgical erectile dysfunction and/or urinary incontinence. Similar to peripheral nerve repair procedures that restore function to the arms and legs, Remplir can be used to protect the NVB from damage and promote restoration of normal nerve function. Remplir has been used In approximately 40 nerve-sparing RARP by urologists across Australia. Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, with data to be released once available. The Company also intends to invest in further research to build evidence and assist medical Education initiatives related to this innovative use of Remplir for peripheral nerve repair. The Company believes the use of Remplir in nerve-sparing RARP represents a significant opportunity to expand Remplir's Total Addressable Market. Remplir rollout in the USD 1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build. Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.お知らせ • Sep 11Orthocell Limited, Annual General Meeting, Nov 06, 2025Orthocell Limited, Annual General Meeting, Nov 06, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 17Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital NetworksOrthocell Limited had secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. A significant portion of these facilities could be serviced by the Company's existing distribution footprint, supporting efficient market penetration. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.お知らせ • Apr 14Orthocell Limited to Report Q3, 2026 Results on Apr 20, 2026Orthocell Limited announced that they will report Q3, 2026 results on Apr 20, 2026お知らせ • Nov 20Orthocell Limited Announces Adoption of Remplir by Australian UrologistsOrthocell Limited announced adoption of Remplir™? by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in 100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. This estimate is based on ~ 115,000 prostatectomies performed annually in the U.S., the majority of which are conducted automatically. To capitalise on this opportunity, the Company is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted U.S. product launch in the medium term. Orthocell is also collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets.お知らせ • Nov 14Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,846,154 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 230,770 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 16Orthocell Limited Announces Nerve-Sparing Prostate Cancer SurgeryOrthocell Limited announced its nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market. Summary Points: Australian urologists are using Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications due to peripheral nerve injury -- a development with potential for globally significant impact. Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate. Despite procedures aimed at preserving nerve function (i.e. nerve-sparing), and with the enhanced surgical precision offered by robotic assisted radical prostatectomies (RARP), there remains a significant risk of post-surgical erectile dysfunction and/or urinary incontinence. Similar to peripheral nerve repair procedures that restore function to the arms and legs, Remplir can be used to protect the NVB from damage and promote restoration of normal nerve function. Remplir has been used In approximately 40 nerve-sparing RARP by urologists across Australia. Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, with data to be released once available. The Company also intends to invest in further research to build evidence and assist medical Education initiatives related to this innovative use of Remplir for peripheral nerve repair. The Company believes the use of Remplir in nerve-sparing RARP represents a significant opportunity to expand Remplir's Total Addressable Market. Remplir rollout in the USD 1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build. Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.お知らせ • Sep 11Orthocell Limited, Annual General Meeting, Nov 06, 2025Orthocell Limited, Annual General Meeting, Nov 06, 2025.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.038 loss per share (vs AU$0.036 loss in FY 2024)Full year 2025 results: AU$0.038 loss per share (further deteriorated from AU$0.036 loss in FY 2024). Revenue: AU$7.55m (up 42% from FY 2024). Net loss: AU$8.57m (loss widened 19% from FY 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 02+ 1 more updateOrthocell Limited Appoints Adam Wood as Chief Commercial OfficerOrthocell Limited announced the appointment of two senior executives to its leadership team. The appointments support the Company's global expansion and commercialisation activities for its regenerative medicine product portfolio, and most notably its nerve repair device, Remplir. The Company has appointed Mr. Adam Wood to the newly created role of Chief Commercial Officer (CCO) to oversee the global sales and marketing of Orthocell's product portfolio. Mr. Wood will drive Orthocell's business development and sales rollout in key global markets, focusing on the US, and lead the worldwide commercialization of Orthocell's intellectual property portfolio. Mr. Wood brings extensive experience in sales and marketing in the healthcare and medical technology sectors, having previously held senior roles at Johnson & Johnson, LifeHealthcare, and most recently EBOS Medical Technology (part of EBOS Group), where he led brand strategy, product marketing, and corporate development as Executive General Manager. Prior to that, Mr. Wood held the role of General Manager, Marketing at Life Healthcare, where, under private equity ownership, he led the expansion of the marketing capabilities in line with the growth of the business (>4 x EBITDA in four years) by attracting high-caliber talent and lifting team engagement scores from 58% to 85%.お知らせ • Apr 10+ 1 more updateOrthocell Limited Receives Regulatory Approval for Striate+ in Brazil: Marks First Market Authorization in Latin AmericaOrthocell Limited announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company's market-leading dental guided bone regeneration product, Striate+™?, for use in guided bone and tissue regeneration applications. Orthocell is working with BioHorizons, the global marketing and distribution partner for Striate+, on an initial launch into the USD 65 million Brazilian dental membrane market and expects to commence commercial distribution of Striate+ in fourth quarter of 2025. Orthocell is working With BioHorizons, the global Marketing and distribution partner for Striate+ on an initial launch into the $65 million Brazilian dental membrane market and expected to commence commercial distribution ofStriate+ in Fourth Quarter CY 2025. Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Orthocell is the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™?, for peripheral nerve reconstruction, is approved in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies Group. SmrtGraft™?, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.お知らせ • Oct 31Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,166,667 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 166,666 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Transaction Features: Subsequent Direct Listingお知らせ • Oct 25Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,166,667 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 166,666 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Transaction Features: Subsequent Direct Listingお知らせ • Oct 04Orthocell Limited, Annual General Meeting, Nov 29, 2024Orthocell Limited, Annual General Meeting, Nov 29, 2024.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023)Full year 2024 results: AU$0.036 loss per share (further deteriorated from AU$0.032 loss in FY 2023). Revenue: AU$5.32m (up 25% from FY 2023). Net loss: AU$7.18m (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Mar 01Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,459,461 Price\Range: AUD 0.37 Transaction Features: Subsequent Direct ListingNew Risk • Feb 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m). Market cap is less than US$100m (AU$88.7m market cap, or US$57.6m).お知らせ • Feb 23Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,459,460 Price\Range: AUD 0.37 Transaction Features: Subsequent Direct Listingお知らせ • Jan 15+ 1 more updateOrthocell Limited Announces Resignation of Matthew Callahan from the BoardOrthocell Limited announced that as part of its Board renewal program and following the appointment of the Hon Kim Beazley AC to the Board, Mr. Matthew Callahan, has resigned from the Board. Following Kim's appointment and the resignation of Matthew Callahan, the Orthocell Board has five Directors comprising four Non-Executive Directors and one Executive Director. With an experienced Board and Management Team, market leading products and strong balance sheet, Orthocell is well positioned to grow product sales alongside its distribution partners, BioHorizons and Device Technologies which includes, as a priority, executing its US market access program and commercialisation strategy for its breakthrough nerve repair medical device, Remplir. The aforementioned Board change is effective from 5.00 pm, 15 January 2024.お知らせ • Dec 22Orthocell Limited Announces Changes to its BoardOrthocell Limited announced that founding Board member and former Chairman, Dr. Stewart Washer, has retired from the Company's Board. Dr. Washer has completed the transition from his previous role as the long-standing Chair and has fully handed over the reins to new Chairman John Van Der Wielen. Stewart made the decision to retire from the Orthocell Board after having served almost 10 years to allow him to pursue other interests. Orthocell Board now has five Directors comprising four Non-Executive Directors and one Executive Director. The recent appointment of Professor Fiona Wood, independent non-executive Director Dr. Ravi Thadhani and Chairman Mr. John Van Der Wielen to the Orthocell Board, has strengthened the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies.お知らせ • Oct 26Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023Orthocell Limited provided commercial revenue guidance for the full year 2023. For the period, the company expects commercial revenue to in the range of $51 million to $53 million.お知らせ • Oct 25Orthocell Limited Announces Board ChangesOrthocell Limited announced the appointment of Professor Fiona Wood AM to the Orthocell Board. This coincides with the retirement of Mr. Qi Xiao Zhou, who has served as a Member of Orthocell’s Board since 2012 and the transition of Dr. Stewart Washer from Executive Director to Non-Executive Director. All changes detailed above will be effective 01 November, 2023. The appointment of Professor Wood follows the recent appointment of experienced Chairman Mr. John Van Der Wielen, and independent Non-Executive USA based Director Dr. Ravi Thadhani. Professor Fiona Wood is a well-known and highly respected West Australian, and Australian National Living Treasure, with more than 30 years’ experience as a plastic and reconstructive surgeon. Professor Wood was named Western Australian Citizen of the Year in 2003 and 2004, Australian of the Year in 2005 and Member of the Order of Australia (AM) in 2003 for her contribution to Medicine in the field of burns. Her revolutionary “spray-on skin” treatment of serious burns, invented with colleague Marie Stoner, uses a patient’s own skin cells to help restore damaged skin and significantly reduce permanent scarring. This treatment was instrumental in saving many lives in the aftermath of the Bali bombing in 2002. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children’s Hospital, and the Winthrop Professor of Surgery at the University of Western Australia. Professor Wood is co-founder of the Wood Foundation, which continues her research into the treatment of burns and is a Board member of the Royal Flying Doctor Service, amongst others. Following Professor Woods’s appointment and the resignation of Mr. Zhou, the Orthocell Board has six Directors comprising four Non-Executive Directors and two Executive Directors. With the experienced Board and management team, market leading products and strong balance sheet, the Company is well positioned to grow product sales alongside distribution partners, BioHorizons and Device Technologies, and to execute its US market access program and commercialisation strategies for its breakthrough nerve repair medical device.Board Change • Oct 06Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Chairman John Van Der Wielen was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Sep 22Orthocell Limited Announces Board ChangesOrthocell Limited announced that Professor Lars Lidgren is retiring from the Orthocell Board, effective from 30 September 2023 and Ms Leslie Wise is taking a temporary leave of absence for personal reasons, effective immediately.お知らせ • Sep 05Orthocell Limited, Annual General Meeting, Oct 31, 2023Orthocell Limited, Annual General Meeting, Oct 31, 2023.Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)Full year 2023 results: AU$0.032 loss per share (improved from AU$0.047 loss in FY 2022). Revenue: AU$4.24m (up 177% from FY 2022). Net loss: AU$6.25m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$79.9m market cap, or US$51.8m).お知らせ • May 30Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023Regenerative medicine company Orthocell Limited announced the appointment of John Van Der Wielen as independent Non-Executive Chairman, effective 1 June 2023. Dr. Stewart Washer, who has served as Executive Chairman since April 2014, will transition to Executive Director. The appointment of Mr. Van Der Wielen follows the recent addition of globally recognised healthcare executive Dr. Ravi Thadhani to the Orthocell Board and will further strengthen the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies. As a senior financial services professional, Mr. Van Der Wielen has over 35 years' international experience in wealth management, private banking, investments, and insurance, in the UK, Luxembourg, Malaysia and Australia. He has held senior executive positions with several national and global financial services groups. Most recently Mr. Van Der Wielen was the CEO and MD of HBF Health Ltd. for over five years. HBF has revenue of over 1.6 billion dollars and in a recent independent consumer survey was named Australia's most trusted brand in private health insurance. Mr. Van Der Wielen's other previous executive positions include CEO (UK & International) of Friends Life UK, Managing Director (Wealth) of ANZ, CEO of Clerical Medical, Halifax Life & Heidelberger Leben and CEO of Lloyds Banking Group/HBOS Plc. Mr. Van Der Wielen has held numerous directorships and advisory positions, including roles as Senior Adviser to Blackstone. He has served as Chairperson of Kyckr, Non-Executive Director of Partners Life, Non- Executive Director of Friends Provident International and Non-Executive Director of Lombard International Assurance. Mr. Van Der Wielen has significant expertise overseeing and chairing large funds management and investment committees, as well as leading on acquisitions, integration and restructuring programs. Mr. Van Der Wielen is currently Non-Executive Director, of the Blackstone owned Crown Resorts and Chair of Crown Perth, and Non-Executive Director of the Royal Flying Doctor Service WA. He is a Senior Adviser to Appian Capital Advisory LLP and was recently appointed by the Western Australian Government to Chair its Future Health Research and Innovation Fund (FHRI). The FHRI is a sovereign wealth fund, with a purpose is to improve, through research and innovation, the health and prosperity of Western Australians, the sustainability of the health system and to advance the State's standing as a leader in research and innovation. Mr. Van Der Wielen holds an MBA from the University of Western Australia, has studied at London Business School and Oxford University, and is a Fellow of the Australian Institute of Company Directors.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)First half 2023 results: AU$0.021 loss per share (improved from AU$0.024 loss in 1H 2022). Net loss: AU$4.06m (loss narrowed 13% from 1H 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)Full year 2022 results: AU$0.047 loss per share. Net loss: AU$9.11m (flat on FY 2021).Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Sep 25CEO, MD & Executive Director recently sold AU$552k worth of stockOn the 23rd of September, Paul Anderson sold around 1m shares on-market at roughly AU$0.48 per share. This was the largest sale by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months.Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 07Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Lars Lidgren was the last independent director to join the board, commencing their role in 2007. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)Full year 2021 results: Net loss: AU$9.04m (loss widened 47% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 04New 90-day high: AU$0.48The company is up 14% from its price of AU$0.42 on 07 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day low: AU$0.33The company is down 6.0% from its price of AU$0.34 on 05 August 2020. The Australian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.株主還元OCCAU BiotechsAU 市場7D2.0%2.1%3.3%1Y-36.0%-51.0%3.9%株主還元を見る業界別リターン: OCC過去 1 年間で-51 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: OCCは、過去 1 年間で3.9 % のリターンを上げたAustralian市場を下回りました。価格変動Is OCC's price volatile compared to industry and market?OCC volatilityOCC Average Weekly Movement9.7%Biotechs Industry Average Movement11.0%Market Average Movement10.3%10% most volatile stocks in AU Market17.5%10% least volatile stocks in AU Market4.1%安定した株価: OCC 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: OCCの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006n/aPaul Andersonorthocell.com再生医療企業であるOrthocell Limitedは、オーストラリア、米国、英国、欧州連合（EU）において、様々な骨・軟部組織の損傷修復のための細胞療法と生物学的医療機器を開発・商品化している。同社は、慢性腱損傷治療用の細胞療法であるOrtho-ATI、歯科治療における骨・組織再生誘導に使用される再吸収性コラーゲン膜であるStriate+、末梢神経修復に使用されるコラーゲン足場であるRemplir、膝や足首の関節軟骨欠損を治療するための自己軟骨細胞移植であるOrtho-ACIを提供している。オーソセル社は2006年に設立され、オーストラリアのマードックに本社を置いている。もっと見るOrthocell Limited 基礎のまとめOrthocell の収益と売上を時価総額と比較するとどうか。OCC 基礎統計学時価総額AU$200.11m収益（TTM）-AU$12.48m売上高(TTM)AU$9.33m21.4xP/Sレシオ-16.0xPER（株価収益率OCC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OCC 損益計算書（TTM）収益AU$9.33m売上原価AU$3.38m売上総利益AU$5.95mその他の費用AU$18.43m収益-AU$12.48m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.046グロス・マージン63.77%純利益率-133.78%有利子負債／自己資本比率0%OCC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/19 16:28終値2026/06/19 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Orthocell Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Brenton AndersonBell PotterShane StoreyCanaccord Genuity
お知らせ • Apr 17Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital NetworksOrthocell Limited had secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. A significant portion of these facilities could be serviced by the Company's existing distribution footprint, supporting efficient market penetration. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.
お知らせ • Apr 14Orthocell Limited to Report Q3, 2026 Results on Apr 20, 2026Orthocell Limited announced that they will report Q3, 2026 results on Apr 20, 2026
お知らせ • Nov 20Orthocell Limited Announces Adoption of Remplir by Australian UrologistsOrthocell Limited announced adoption of Remplir™? by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in 100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. This estimate is based on ~ 115,000 prostatectomies performed annually in the U.S., the majority of which are conducted automatically. To capitalise on this opportunity, the Company is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted U.S. product launch in the medium term. Orthocell is also collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets.
お知らせ • Nov 14Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,846,154 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 230,770 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 16Orthocell Limited Announces Nerve-Sparing Prostate Cancer SurgeryOrthocell Limited announced its nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market. Summary Points: Australian urologists are using Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications due to peripheral nerve injury -- a development with potential for globally significant impact. Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate. Despite procedures aimed at preserving nerve function (i.e. nerve-sparing), and with the enhanced surgical precision offered by robotic assisted radical prostatectomies (RARP), there remains a significant risk of post-surgical erectile dysfunction and/or urinary incontinence. Similar to peripheral nerve repair procedures that restore function to the arms and legs, Remplir can be used to protect the NVB from damage and promote restoration of normal nerve function. Remplir has been used In approximately 40 nerve-sparing RARP by urologists across Australia. Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, with data to be released once available. The Company also intends to invest in further research to build evidence and assist medical Education initiatives related to this innovative use of Remplir for peripheral nerve repair. The Company believes the use of Remplir in nerve-sparing RARP represents a significant opportunity to expand Remplir's Total Addressable Market. Remplir rollout in the USD 1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build. Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.
お知らせ • Sep 11Orthocell Limited, Annual General Meeting, Nov 06, 2025Orthocell Limited, Annual General Meeting, Nov 06, 2025.
お知らせ • Apr 17Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital NetworksOrthocell Limited had secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. A significant portion of these facilities could be serviced by the Company's existing distribution footprint, supporting efficient market penetration. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.
お知らせ • Apr 14Orthocell Limited to Report Q3, 2026 Results on Apr 20, 2026Orthocell Limited announced that they will report Q3, 2026 results on Apr 20, 2026
お知らせ • Nov 20Orthocell Limited Announces Adoption of Remplir by Australian UrologistsOrthocell Limited announced adoption of Remplir™? by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in 100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. This estimate is based on ~ 115,000 prostatectomies performed annually in the U.S., the majority of which are conducted automatically. To capitalise on this opportunity, the Company is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted U.S. product launch in the medium term. Orthocell is also collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets.
お知らせ • Nov 14Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,846,154 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 230,770 Price\Range: AUD 1.3 Discount Per Security: AUD 0.065 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 16Orthocell Limited Announces Nerve-Sparing Prostate Cancer SurgeryOrthocell Limited announced its nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market. Summary Points: Australian urologists are using Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications due to peripheral nerve injury -- a development with potential for globally significant impact. Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate. Despite procedures aimed at preserving nerve function (i.e. nerve-sparing), and with the enhanced surgical precision offered by robotic assisted radical prostatectomies (RARP), there remains a significant risk of post-surgical erectile dysfunction and/or urinary incontinence. Similar to peripheral nerve repair procedures that restore function to the arms and legs, Remplir can be used to protect the NVB from damage and promote restoration of normal nerve function. Remplir has been used In approximately 40 nerve-sparing RARP by urologists across Australia. Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, with data to be released once available. The Company also intends to invest in further research to build evidence and assist medical Education initiatives related to this innovative use of Remplir for peripheral nerve repair. The Company believes the use of Remplir in nerve-sparing RARP represents a significant opportunity to expand Remplir's Total Addressable Market. Remplir rollout in the USD 1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build. Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.
お知らせ • Sep 11Orthocell Limited, Annual General Meeting, Nov 06, 2025Orthocell Limited, Annual General Meeting, Nov 06, 2025.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.038 loss per share (vs AU$0.036 loss in FY 2024)Full year 2025 results: AU$0.038 loss per share (further deteriorated from AU$0.036 loss in FY 2024). Revenue: AU$7.55m (up 42% from FY 2024). Net loss: AU$8.57m (loss widened 19% from FY 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 02+ 1 more updateOrthocell Limited Appoints Adam Wood as Chief Commercial OfficerOrthocell Limited announced the appointment of two senior executives to its leadership team. The appointments support the Company's global expansion and commercialisation activities for its regenerative medicine product portfolio, and most notably its nerve repair device, Remplir. The Company has appointed Mr. Adam Wood to the newly created role of Chief Commercial Officer (CCO) to oversee the global sales and marketing of Orthocell's product portfolio. Mr. Wood will drive Orthocell's business development and sales rollout in key global markets, focusing on the US, and lead the worldwide commercialization of Orthocell's intellectual property portfolio. Mr. Wood brings extensive experience in sales and marketing in the healthcare and medical technology sectors, having previously held senior roles at Johnson & Johnson, LifeHealthcare, and most recently EBOS Medical Technology (part of EBOS Group), where he led brand strategy, product marketing, and corporate development as Executive General Manager. Prior to that, Mr. Wood held the role of General Manager, Marketing at Life Healthcare, where, under private equity ownership, he led the expansion of the marketing capabilities in line with the growth of the business (>4 x EBITDA in four years) by attracting high-caliber talent and lifting team engagement scores from 58% to 85%.
お知らせ • Apr 10+ 1 more updateOrthocell Limited Receives Regulatory Approval for Striate+ in Brazil: Marks First Market Authorization in Latin AmericaOrthocell Limited announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company's market-leading dental guided bone regeneration product, Striate+™?, for use in guided bone and tissue regeneration applications. Orthocell is working with BioHorizons, the global marketing and distribution partner for Striate+, on an initial launch into the USD 65 million Brazilian dental membrane market and expects to commence commercial distribution of Striate+ in fourth quarter of 2025. Orthocell is working With BioHorizons, the global Marketing and distribution partner for Striate+ on an initial launch into the $65 million Brazilian dental membrane market and expected to commence commercial distribution ofStriate+ in Fourth Quarter CY 2025. Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Orthocell is the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™?, for peripheral nerve reconstruction, is approved in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies Group. SmrtGraft™?, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.
お知らせ • Oct 31Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,166,667 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 166,666 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 25Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,166,667 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 166,666 Price\Range: AUD 0.6 Discount Per Security: AUD 0.03 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 04Orthocell Limited, Annual General Meeting, Nov 29, 2024Orthocell Limited, Annual General Meeting, Nov 29, 2024.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023)Full year 2024 results: AU$0.036 loss per share (further deteriorated from AU$0.032 loss in FY 2023). Revenue: AU$5.32m (up 25% from FY 2023). Net loss: AU$7.18m (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Mar 01Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,459,461 Price\Range: AUD 0.37 Transaction Features: Subsequent Direct Listing
New Risk • Feb 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m). Market cap is less than US$100m (AU$88.7m market cap, or US$57.6m).
お知らせ • Feb 23Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,459,460 Price\Range: AUD 0.37 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 15+ 1 more updateOrthocell Limited Announces Resignation of Matthew Callahan from the BoardOrthocell Limited announced that as part of its Board renewal program and following the appointment of the Hon Kim Beazley AC to the Board, Mr. Matthew Callahan, has resigned from the Board. Following Kim's appointment and the resignation of Matthew Callahan, the Orthocell Board has five Directors comprising four Non-Executive Directors and one Executive Director. With an experienced Board and Management Team, market leading products and strong balance sheet, Orthocell is well positioned to grow product sales alongside its distribution partners, BioHorizons and Device Technologies which includes, as a priority, executing its US market access program and commercialisation strategy for its breakthrough nerve repair medical device, Remplir. The aforementioned Board change is effective from 5.00 pm, 15 January 2024.
お知らせ • Dec 22Orthocell Limited Announces Changes to its BoardOrthocell Limited announced that founding Board member and former Chairman, Dr. Stewart Washer, has retired from the Company's Board. Dr. Washer has completed the transition from his previous role as the long-standing Chair and has fully handed over the reins to new Chairman John Van Der Wielen. Stewart made the decision to retire from the Orthocell Board after having served almost 10 years to allow him to pursue other interests. Orthocell Board now has five Directors comprising four Non-Executive Directors and one Executive Director. The recent appointment of Professor Fiona Wood, independent non-executive Director Dr. Ravi Thadhani and Chairman Mr. John Van Der Wielen to the Orthocell Board, has strengthened the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies.
お知らせ • Oct 26Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023Orthocell Limited provided commercial revenue guidance for the full year 2023. For the period, the company expects commercial revenue to in the range of $51 million to $53 million.
お知らせ • Oct 25Orthocell Limited Announces Board ChangesOrthocell Limited announced the appointment of Professor Fiona Wood AM to the Orthocell Board. This coincides with the retirement of Mr. Qi Xiao Zhou, who has served as a Member of Orthocell’s Board since 2012 and the transition of Dr. Stewart Washer from Executive Director to Non-Executive Director. All changes detailed above will be effective 01 November, 2023. The appointment of Professor Wood follows the recent appointment of experienced Chairman Mr. John Van Der Wielen, and independent Non-Executive USA based Director Dr. Ravi Thadhani. Professor Fiona Wood is a well-known and highly respected West Australian, and Australian National Living Treasure, with more than 30 years’ experience as a plastic and reconstructive surgeon. Professor Wood was named Western Australian Citizen of the Year in 2003 and 2004, Australian of the Year in 2005 and Member of the Order of Australia (AM) in 2003 for her contribution to Medicine in the field of burns. Her revolutionary “spray-on skin” treatment of serious burns, invented with colleague Marie Stoner, uses a patient’s own skin cells to help restore damaged skin and significantly reduce permanent scarring. This treatment was instrumental in saving many lives in the aftermath of the Bali bombing in 2002. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children’s Hospital, and the Winthrop Professor of Surgery at the University of Western Australia. Professor Wood is co-founder of the Wood Foundation, which continues her research into the treatment of burns and is a Board member of the Royal Flying Doctor Service, amongst others. Following Professor Woods’s appointment and the resignation of Mr. Zhou, the Orthocell Board has six Directors comprising four Non-Executive Directors and two Executive Directors. With the experienced Board and management team, market leading products and strong balance sheet, the Company is well positioned to grow product sales alongside distribution partners, BioHorizons and Device Technologies, and to execute its US market access program and commercialisation strategies for its breakthrough nerve repair medical device.
Board Change • Oct 06Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Chairman John Van Der Wielen was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Sep 22Orthocell Limited Announces Board ChangesOrthocell Limited announced that Professor Lars Lidgren is retiring from the Orthocell Board, effective from 30 September 2023 and Ms Leslie Wise is taking a temporary leave of absence for personal reasons, effective immediately.
お知らせ • Sep 05Orthocell Limited, Annual General Meeting, Oct 31, 2023Orthocell Limited, Annual General Meeting, Oct 31, 2023.
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)Full year 2023 results: AU$0.032 loss per share (improved from AU$0.047 loss in FY 2022). Revenue: AU$4.24m (up 177% from FY 2022). Net loss: AU$6.25m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$79.9m market cap, or US$51.8m).
お知らせ • May 30Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023Regenerative medicine company Orthocell Limited announced the appointment of John Van Der Wielen as independent Non-Executive Chairman, effective 1 June 2023. Dr. Stewart Washer, who has served as Executive Chairman since April 2014, will transition to Executive Director. The appointment of Mr. Van Der Wielen follows the recent addition of globally recognised healthcare executive Dr. Ravi Thadhani to the Orthocell Board and will further strengthen the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies. As a senior financial services professional, Mr. Van Der Wielen has over 35 years' international experience in wealth management, private banking, investments, and insurance, in the UK, Luxembourg, Malaysia and Australia. He has held senior executive positions with several national and global financial services groups. Most recently Mr. Van Der Wielen was the CEO and MD of HBF Health Ltd. for over five years. HBF has revenue of over 1.6 billion dollars and in a recent independent consumer survey was named Australia's most trusted brand in private health insurance. Mr. Van Der Wielen's other previous executive positions include CEO (UK & International) of Friends Life UK, Managing Director (Wealth) of ANZ, CEO of Clerical Medical, Halifax Life & Heidelberger Leben and CEO of Lloyds Banking Group/HBOS Plc. Mr. Van Der Wielen has held numerous directorships and advisory positions, including roles as Senior Adviser to Blackstone. He has served as Chairperson of Kyckr, Non-Executive Director of Partners Life, Non- Executive Director of Friends Provident International and Non-Executive Director of Lombard International Assurance. Mr. Van Der Wielen has significant expertise overseeing and chairing large funds management and investment committees, as well as leading on acquisitions, integration and restructuring programs. Mr. Van Der Wielen is currently Non-Executive Director, of the Blackstone owned Crown Resorts and Chair of Crown Perth, and Non-Executive Director of the Royal Flying Doctor Service WA. He is a Senior Adviser to Appian Capital Advisory LLP and was recently appointed by the Western Australian Government to Chair its Future Health Research and Innovation Fund (FHRI). The FHRI is a sovereign wealth fund, with a purpose is to improve, through research and innovation, the health and prosperity of Western Australians, the sustainability of the health system and to advance the State's standing as a leader in research and innovation. Mr. Van Der Wielen holds an MBA from the University of Western Australia, has studied at London Business School and Oxford University, and is a Fellow of the Australian Institute of Company Directors.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)First half 2023 results: AU$0.021 loss per share (improved from AU$0.024 loss in 1H 2022). Net loss: AU$4.06m (loss narrowed 13% from 1H 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)Full year 2022 results: AU$0.047 loss per share. Net loss: AU$9.11m (flat on FY 2021).
Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Sep 25CEO, MD & Executive Director recently sold AU$552k worth of stockOn the 23rd of September, Paul Anderson sold around 1m shares on-market at roughly AU$0.48 per share. This was the largest sale by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months.
Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 07Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Lars Lidgren was the last independent director to join the board, commencing their role in 2007. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)Full year 2021 results: Net loss: AU$9.04m (loss widened 47% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 04New 90-day high: AU$0.48The company is up 14% from its price of AU$0.42 on 07 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day low: AU$0.33The company is down 6.0% from its price of AU$0.34 on 05 August 2020. The Australian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
